HomeBUSINESS
BUSINESS

Aducanumab Trial Tweak Has No Impact on Probability of Success: Eisai CEO
(Mar.9.2018)

Eisai CEO Haruo Naito stressed on March 8 that PIII trials being conducted with Biogen on Alzheimer’s hopeful aducanumab is “steadily ongoing,” noting that a 500-plus increase in their sample size has “no impact” on the odds of success of those studies ...
(LOG IN FOR FULL STORY)